Bayer AG enters into collaborations to develop a heart-targeted siRNA therapy and AI technology, expanding its push into next ...

Ribo's IPO is aiming to raise around HKD 1.59 billion (around $205 million) through the sale of 27.5 million shares at HKD 57 ...

The discovery of siRNA and its role in RNAi was a groundbreaking finding in the field of molecular biology. In 1998, Andrew Fire and Craig Mello published a seminal paper describing the phenomenon of ...

Please provide your email address to receive an email when new articles are posted on . In this video, Yancy, a professor and chief of cardiology at Northwestern University Feinberg School of Medicine ...

Ribo Life Science Co., Ltd. ('Ribo' or the 'Company', stock code: 06938.HK), a leading company in small interfering RNA ...

Arrowhead Pharmaceuticals has received authorisation from Health Canada for its small interfering RNA (siRNA) medicine, ...

In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in blood ...

CHICAGO -- Novel small interfering RNA (siRNA) agent lepodisiran drastically cut levels of lipoprotein(a), or Lp(a), in the phase II ALPACA trial. The 400-mg dose cut Lp(a) by 93.9 percentage points ...

Please provide your email address to receive an email when new articles are posted on . Investigational therapies to lower Lp(a) include antisense oligonucleotide therapies and small interfering RNA ...

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and ...